Servier’s Voranigo backed by MHRA for astrocytoma or oligodendroglioma

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has today approved independent French pharma major Servier’s Voranigo (vorasidenib) to treat adults and children 12 years of age and older with certain types of brain tumors, known as grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase mutation (IDH1 or IDH2).

The medicine is for patients who are not in need of immediate chemotherapy or radiotherapy following surgical intervention, the Agency noted.

Servier gained rights to vorasidenib when it acquired Agios Pharmaceuticals' oncology business for $2 billion in 2021. The drug gained US regulatory approval in August last year. It was also recommended for approval by the European Medicines’ (EMA) human medicines committee (CHMP) in July this year.